{"id":"polymixin-bacitracin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nephrotoxicity"},{"rate":"5-15%","effect":"Ototoxicity"},{"rate":"5-10%","effect":"Neuromuscular blockade"}]},"_chembl":{"chemblId":"CHEMBL1200558","moleculeType":"Protein","molecularWeight":"1422.72"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Polymyxin B binds to the bacterial cell membrane, causing a disruption in the cell membrane's structure and function. Bacitracin inhibits the synthesis of the bacterial cell wall by inhibiting the enzyme responsible for the formation of the cell wall. This combination of actions results in the death of the bacterial cell.","oneSentence":"Polymyxin B and bacitracin work together to inhibit bacterial cell wall synthesis and disrupt bacterial cell membranes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:28.970Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of infections caused by susceptible strains of Staphylococcus aureus, Escherichia coli, and Klebsiella-Enterobacter species."}]},"trialDetails":[{"nctId":"NCT02809131","phase":"PHASE3","title":"Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2016-04-01","conditions":"Sick Sinus Syndrome, Complete Heart Block, Syncope","enrollment":1010},{"nctId":"NCT00990392","phase":"NA","title":"Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections","status":"WITHDRAWN","sponsor":"Fraser Health","startDate":"2009-11","conditions":"Blood Stream Infections, Skin Diseases, Infectious","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"polymixin/bacitracin","genericName":"polymixin/bacitracin","companyName":"Vanderbilt University Medical Center","companyId":"vanderbilt-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Polymixin/bacitracin is a topical antibiotic used to treat various conditions, including blood stream infections and skin diseases, as well as prevent central line infections in intensive care units. It works by inhibiting C55-isoprenyl pyrophosphate, a protein involved in bacterial cell wall synthesis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}